Propafenone

Propafenone
Clinical data


Trade names	Rythmol
AHFS/Drugs.com	Monograph
MedlinePlus	a698002
Pregnancy category	C
Routes of administration	Oral
ATC code	C01BC03 (WHO)
Legal status
Legal status	Prescription only
Pharmacokinetic data
Bioavailability	?
Protein binding	97%
Biological half-life	2-10 hours
Identifiers
IUPAC name 1-{2-[2-Hydroxy-3-(propylamino)propoxy]phenyl}-3-phenylpropan-1-one
CAS Number	54063-53-5^Y
PubChem (CID)	4932
IUPHAR/BPS	2561
DrugBank	DB01182^Y
ChemSpider	4763^Y
UNII	68IQX3T69U^Y
KEGG	D08435^Y
ChEMBL	CHEMBL631^Y
ECHA InfoCard	100.053.578
Chemical and physical data
Formula	C₂₁H₂₇NO₃
Molar mass	341.444 g/mol
3D model (Jmol)	Interactive image
SMILES O=C(c1ccccc1OCC(O)CNCCC)CCc2ccccc2
InChI InChI=1S/C21H27NO3/c1-2-14-22-15-18(23)16-25-21-11-7-6-10-19(21)20(24)13-12-17-8-4-3-5-9-17/h3-11,18,22-23H,2,12-16H2,1H3^Y Key:JWHAUXFOSRPERK-UHFFFAOYSA-N^Y

Propafenone (/proʊˈpæfᵻnoʊn/ proh-PAF-i-nohn; brand name Rythmol SR or Rytmonorm) is a class 1C anti-arrhythmic medication, which treats illnesses associated with rapid heart beats such as atrial and ventricular arrhythmias.

Propafenone works by slowing the influx of sodium ions into the cardiac muscle cells, causing a decrease in excitability of the cells. Propafenone is more selective for cells with a high rate, but also blocks normal cells more than class Ia or Ib. Propafenone differs from the prototypical class Ic antiarrhythmic in that it has additional activity as a beta-adrenergic blocker which can cause bradycardia and bronchospasm.

Propafenone is metabolized primarily in the liver. Because of its short half-life, it requires dosing two or three times daily to maintain steady blood levels. The long-term safety of propafenone is unknown. Because it is structurally similar to another anti-arrhythmic medicine, flecainide, similar cautions should be exercised in its use. Flecainide and propafenone, like other antiarrhythmic drugs have been shown to increase the occurrence of arrhythmias (5.3% for propafenone, Teva physician prescribing information), primarily in patients with underlying heart disease. However, their use in structurally normal hearts is considered safe.

...
Wikipedia